AARDVARK THERAPEUTICS, INC. Comprehensive Income
AARDVARK THERAPEUTICS, INC. (AARD) reported Comprehensive Income of -$14.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$14.40M.
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$21.66M.
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$17.60M.
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$16.23M.
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$57.51M.
- AARDVARK THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$20.59M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.40M 10-Q · filed 2026-08-11 | -$36.06M 10-Q · filed 2026-08-11 | -$53.66M derived: sum of 3 quarters · filed 2026-08-11 | -$69.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$21.66M 10-Q · filed 2026-05-07 | -$39.25M derived: sum of 2 quarters · filed 2026-05-07 | -$55.48M derived: sum of 3 quarters · filed 2026-05-07 | -$69.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$17.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$33.83M derived: sum of 2 quarters · filed 2026-03-23 | -$48.24M derived: sum of 3 quarters · filed 2026-08-11 | -$57.51M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$16.23M 10-Q · filed 2025-11-13 | -$30.64M derived: sum of 2 quarters · filed 2026-08-11 | -$39.91M 10-Q · filed 2025-11-13 | -$48.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$14.41M 10-Q · filed 2026-08-11 | -$23.68M 10-Q · filed 2026-08-11 | -$32.46M derived: sum of 3 quarters · filed 2026-08-11 | -$36.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$9.27M 10-Q · filed 2026-05-07 | -$18.05M derived: sum of 2 quarters · filed 2026-05-07 | -$22.23M derived: sum of 3 quarters · filed 2026-05-07 | -$27.68M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$8.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$12.96M derived: sum of 2 quarters · filed 2026-03-23 | -$18.41M derived: sum of 3 quarters · filed 2026-03-23 | -$20.59M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$4.18M 10-Q · filed 2025-11-13 | -$9.63M derived: sum of 2 quarters · filed 2025-11-13 | -$11.81M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$5.45M 10-Q · filed 2025-08-13 | -$7.63M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$2.18M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |